Sofinnova closes €725 million fund to back European biotech expansion

By Reuters News

By Bhanvi Satija

- Life sciences investment firm Sofinnova Partners said on Monday it has closed a second crossover fund at €725 million ($799 million), above its original target, to back European biotechs that are seeking to compete globally.

A crossover fund typically invests in private companies approaching commercialisation or public listings, bridging the gap between venture capital and public-market investing.

The raise comes at a time when drugmakers are pushing European governments to increase spending on medicines, faster trials and other policies that would prevent the region from losing ground to the US and China.

At the same time, cash-strapped governments in Europe are under pressure to rethink how they pay for innovative medicines.

Europe has outstanding science and companies, said Kinam Hong, a partner at Sofinnova, told Reuters in an interview.

"It doesn’t have an innovation gap, but it really has a financing growth capital problem," he said.

Hong said the fund, called Crossover II, is the biggest ever for the firm and will focus on European biotechs and medtech companies looking to commercialise their medicines or devices, with some selective investments in the US and elsewhere.

Through the fund, Sofinnova expects to back about 15 companies and has already invested in rare-disease biotech Hemab Therapeutics, multiple myeloma drug developer CellCentric and Neurent Medical, a chronic rhinitis device maker.

Hong said the firm plans to be an active investor, helping companies with leadership, trials and listings. He added that the aim is to build companies for "successful longevity" even without mergers and acquisitions.

The firm's first Crossover fund had backed Amolyt Pharma, a developer of treatments for rare hormone disorders that was acquired by AstraZeneca AZN.L, as well as the French biotech Abivax ABVX.PA, which is developing an ulcerative colitis drug.

Sofinnova manages more than €4 billion ($4.4 billion) in assets across healthcare and sustainability.

($1 = 0.9073 euros)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.